Oct 3, 2025 04:09PM Seres Therapeutics cuts workforce 25% to extend cash runway

Sep 24, 2025 06:28AM Seres Therapeutics (MCRB) PT Raised to $22 at Canaccord Genuity

Aug 6, 2025 07:52AM Seres Therapeutics (MCRB) Misses Q2 EPS by 218c

Jul 22, 2025 07:07AM Seres Therapeutics names co-CEOs as current chief executive steps down

May 27, 2025 07:02AM Seres Therapeutics (MCRB) Presents Expanded SER-155 Exploratory Biomarker Data

May 8, 2025 05:06AM Chardan Capital Markets Downgrades Seres Therapeutics (MCRB) to Neutral

Mar 13, 2025 07:06AM Seres Therapeutics (MCRB) Misses Q4 EPS by 61c

Mar 3, 2025 07:00AM Seres Therapeutics (MCRB) Receives Feedback From FDA on SER-155

Jan 16, 2025 07:01AM Seres Therapeutics (MCRB) Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

Dec 9, 2024 07:06AM Seres Therapeutics (MCRB) : FDA Grants Breakthrough Therapy Designation to SER-155 for Reduction of Bloodstream Infections in Adults Undergoing allo-HSCT

Nov 13, 2024 07:36AM Seres Therapeutics (MCRB) Misses Q3 EPS by 25c

Oct 24, 2024 03:46AM JPMorgan Downgrades Seres Therapeutics (MCRB) to Underweight

Oct 1, 2024 04:51PM Seres Therapeutics (MCRB) Files for 14.29M Share Offering by Selling Stockholders

Sep 27, 2024 03:28PM Seres Therapeutics (MCRB) Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé

Sep 26, 2024 04:01PM Seres Therapeutics (MCRB) Stockholders Approve Sale of VOWST to Nestle Health Science

Sep 12, 2024 02:38PM TD Cowen Reiterates Buy Rating on Seres Therapeutics (MCRB)

Sep 12, 2024 07:02AM Seres Therapeutics (MCRB) Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Aug 13, 2024 07:03AM Seres Therapeutics (MCRB) Tops Q2 EPS by 5c

Aug 6, 2024 07:03AM Seres Therapeutics (MCRB) Announces Signing of VOWST Asset Purchase Agreement with Nestlé Health Science